Proprietary AI analyst is now available
- Public Comps
- Horiba
Horiba Valuation Multiples
Discover Horiba's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Shimadzu, Sectra, Asahi Intecc, Sensata Technologies and more.
Horiba Overview
About Horiba
Horiba Ltd provides analytical and measurement equipment. The company operates through five segments. The Automobile segment offers automotive validation, verification technologies, and consulting services. The Environment/Accounting Process segment provides measurement technologies for air, water, and soil quality to support environmental conservation. The Medical segment develops and distributes in vitro diagnostic systems, mainly in the field of hematology. The Science segment delivers high-performance scientific instruments and analytical solutions. The Semiconductor segment specializes in fluid control, measurement, and analysis technologies for researchers, developers, and manufacturers across regions.
Founded
1953
HQ

Employees
9.0K
Website
Financials (LTM)
EV
$6B
Valuation Multiples
Start free trialHoriba Financials
Horiba reported last 12-month revenue of $2B and EBITDA of $468M.
In the same LTM period, Horiba generated $998M in gross profit, $468M in EBITDA, and $265M in net income.
Revenue (LTM)
Horiba P&L
In the most recent fiscal year, Horiba reported revenue of $2B and EBITDA of $434M.
Horiba is profitable as of last fiscal year, with gross margin of 42%, EBITDA margin of 20%, and net margin of 11%.
Financial data powered by Morningstar, Inc.
Horiba Stock Performance
Horiba has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Horiba's stock price is $158.80.
Horiba share price decreased by 3.7% in the last 30 days, and increased by 124.2% in the last year.
Horiba has an EPS (earnings per share) of $5.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | -0.1% | -3.7% | 41.2% | 124.2% | $5.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHoriba Valuation Multiples
Horiba trades at 2.7x EV/Revenue multiple, and 13.0x EV/EBITDA.
EV / Revenue (LTM)
Horiba Financial Valuation Multiples
As of June 14, 2026, Horiba has market cap of $7B and EV of $6B.
Horiba has a P/E ratio of 25.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Horiba Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Horiba Margins & Growth Rates
Horiba grew revenue by 6% and EBITDA by 17% in the last fiscal year.
In the most recent fiscal year, Horiba reported gross margin of 42%, EBITDA margin of 20%, and net margin of 11%.
Horiba Margins
Horiba Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Horiba Operational KPIs
Horiba's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Horiba's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Horiba's Rule of X is 48% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Horiba Competitors
Horiba competitors include Shimadzu, Sectra, Asahi Intecc, Sensata Technologies, Glaukos, Abbott India, Teleflex, Ypsomed, Novanta and Getinge.
Most Horiba public comparables operate across Medical Devices, Test & Measurement, DeepTech, HealthTech and Industry 4.0.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.7x | 1.6x | 10.0x | 9.5x | |||
| 15.9x | 15.8x | 67.8x | 66.3x | |||
| 7.0x | 6.4x | 21.1x | 17.6x | |||
| 2.6x | 2.5x | 11.2x | 10.9x | |||
| 14.3x | 12.9x | (220.8x) | 1174.4x | |||
| 7.7x | 7.6x | 24.6x | 27.7x | |||
| 4.1x | 3.8x | 13.4x | 13.4x | |||
| 6.5x | 6.6x | 14.7x | 14.9x | |||
This data is available for Pro users. Sign up to see all Horiba competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Horiba
Horiba has acquired 2 companies to date.
Last acquisition by Horiba was on February 3rd 2021. Horiba acquired MedTest DX for undisclosed valuation.
Latest Acquisitions by Horiba
| Description | MedTest DX is a Cortlandt Manor-based supplier of clinical chemistry analyzers, reagents, and maintenance services to physician offices, hospitals, and reference labs throughout the United States. Founded in 2011, the company distributes the SPOTCHEM EZ dry chemistry analyzer for point-of-care testing of glucose, cholesterol, and electrolytes in 8 to 15 minutes. Its Poly-Chem 90 and 180 models support over 70 FDA-cleared assays with integrated data management for high-volume labs. | FuelCon AG is a Barleben-headquartered provider of test stations and evaluation platforms for fuel cells, batteries, and electrolyzers in the e-mobility sector. The firm's ReadMesH technology enables precise diagnosis of stack performance for automotive developers in Germany and globally. |
| HQ Country | ||
| HQ City | New York City, NY | Magdeburg |
| Deal Date | 3 Feb 2021 | 10 Aug 2018 |
| Valuation | undisclosed | $18M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Horiba acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Horiba
Horiba has invested in 1 company to date.
Latest investment by Horiba was on February 27th 2015. Horiba invested in IPS Portal in their $12M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Horiba
| Description | iPS PORTAL is a Kobe, Japan-based biotechnology service provider specializing in contract testing and quality assurance for induced pluripotent stem (iPS) cells to support research and therapeutic development. The company operates under the Center for iPS Cell Research Application at Kyoto University, offering assays for pluripotency, genetic stability, and differentiation potential. iPS PORTAL facilitates global adoption of iPS technology through standardized testing protocols compliant with Japanese and international regulations, serving academic institutions, pharmaceutical companies, and regenerative medicine firms across Asia and Europe. |
| HQ Country | |
| HQ City | Kyoto |
| Deal Date | 27 Feb 2015 |
| Round | Series A |
| Raised | $12M |
| Investors | Ajinomoto; Chugai Pharma; Daiichi Jitsugyo; Daiwa Securities Group; Eisai Co.; Horiba; SCREEN Holdings Co.; Shimadzu; Shin Nippon Biomedical; SMBC Venture Capital; Sumitomo Mitsui Trust Bank; Sysmex |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Horiba investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Horiba
| When was Horiba founded? | Horiba was founded in 1953. |
| Where is Horiba headquartered? | Horiba is headquartered in Japan. |
| How many employees does Horiba have? | As of today, Horiba has over 9K employees. |
| Who is the CEO of Horiba? | Horiba's CEO is Atsushi Horiba. |
| Is Horiba publicly listed? | Yes, Horiba is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Horiba? | Horiba trades under 6856 ticker. |
| When did Horiba go public? | Horiba went public in 1974. |
| Who are competitors of Horiba? | Horiba main competitors include Shimadzu, Sectra, Asahi Intecc, Sensata Technologies, Glaukos, Abbott India, Teleflex, Ypsomed, Novanta, Getinge. |
| What is the current market cap of Horiba? | Horiba's current market cap is $7B. |
| What is the current revenue of Horiba? | Horiba's last 12 months revenue is $2B. |
| What is the current revenue growth of Horiba? | Horiba revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Horiba? | Current revenue multiple of Horiba is 2.7x. |
| What is the current EBITDA of Horiba? | Horiba's last 12 months EBITDA is $468M. |
| What is Horiba's EBITDA margin? | Horiba's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Horiba? | Current EBITDA multiple of Horiba is 13.0x. |
| What is the current FCF of Horiba? | Horiba's last 12 months FCF is $182M. |
| What is Horiba's FCF margin? | Horiba's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Horiba? | Current FCF multiple of Horiba is 33.5x. |
| How many companies Horiba has acquired to date? | As of June 2026, Horiba has acquired 2 companies. |
| What was the largest acquisition by Horiba? | $18M acquisition of FuelCon AG on 10th August 2018 was the largest M&A Horiba has done to date. |
| What companies Horiba acquired? | Horiba acquired FuelCon AG and MedTest DX. |
| In how many companies Horiba has invested to date? | As of June 2026, Horiba has invested in 1 company. |
| What was the last Horiba investment? | On 27th February 2015 Horiba invested in IPS Portal, participating in a $12M Series A round, alongside Ajinomoto, Chugai Pharma, Daiichi Jitsugyo, Daiwa Securities Group, Eisai Co., SCREEN Holdings Co., Shimadzu, Shin Nippon Biomedical, SMBC Venture Capital, Sumitomo Mitsui Trust Bank, and 1 other investor. |
| In what companies Horiba invested in? | Horiba invested in IPS Portal. |
See public comps similar to Horiba
Lists including Horiba
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


